Life Science Leader Magazine

JAN 2014

The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute

Issue link: https://lifescienceleadermag.epubxp.com/i/233442

Contents of this Issue

Navigation

Page 13 of 53

CAPITOL PERSPECTIVES ers as they have for their retirees' drug coverage. My first column for Life Science Leader, published last spring, detailed the compelling math for an employer of lower- or middle-income workers to dump their employees into Obamacare. The modest $2,000 penalty for large employers failing to provide coverage pales in comparison to the substantial subsidies available in Obamacare to lower- and middle-income workers. For example, an employer offering typical coverage to a family of four with an income of $48,000 would save $7,400, even after it covers the increased income and payroll taxes that result from moving nontaxable benefits into taxable wages. So the real risk is not whether too few sign up for Obamacare, but too many. The Congressional Budget Office predicts that only 8 million individuals will lose their employer-sponsored coverage. But if just 10 percent of employees with employer-sponsored coverage are dumped into the exchange, that number will double to 16 million. Employer dumping of coverage will result in painful coverage disruptions with more narrow provider networks and tighter drug formularies in Obamacare. Just as importantly, it will require greater government subsidies that will, in turn, result in greater scrutiny over pricing and increased pressure to restrain costs. John McManus is president and founder of The McManus Group, a consulting firm specializing in strategic policy and political counsel and advocacy for healthcare clients with issues before Congress and the administration. Prior to founding his firm, McManus served Chairman Bill Thomas as the staff director of the Ways and Means Health Subcommittee, where he led the policy development, negotiations, and drafting of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Before working for Chairman Thomas, McManus worked for Eli Lilly & Company as a senior associate and for the Maryland House of Delegates as a research analyst. He earned his Master of Public Policy from Duke University and Bachelor of Arts from Washington and Lee University. He can be reached at jmcmanus@mcmanusgrp.com. 12 LifeScienceLeader.com January 2014

Articles in this issue

Links on this page

Archives of this issue

view archives of Life Science Leader Magazine - JAN 2014